On May 18, 2017 Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet medical need, reported that SL-401 Stage 1 and 2 data from its ongoing pivotal Phase 2 trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been accepted for poster presentation at the 2017 European Hematology Association (EHA) (Free EHA Whitepaper) Annual Meeting, to be held June 22-25, 2017 in Madrid, Spain (Press release, Stemline Therapeutics, MAY 18, 2017, View Source [SID1234519227]). Schedule your 30 min Free 1stOncology Demo! Details on the presentation is as follows:
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
SL-401 – BPDCN Presentation
Title: Ongoing Phase 2 Clinical Trial Of SL-401 In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Stage 1 And Stage 2 Results
Presenter: Naveen Pemmaraju, MD; MD Anderson Cancer Center
Abstract: P191
Session: Acute myeloid leukemia – Clinical 1
Date/Time: Friday, June 23 – 5:15-6:45 PM CET
Location: Hall 7 – Poster Area
Stemline remains on track to provide an update on BPDCN patients enrolled in Stage 3 of the Phase 2 pivotal trial in the second half of this year.